Snehal Patel - 22 Jun 2022 Form 4 Insider Report for Greenwich LifeSciences, Inc. (GLSI)

Role
CEO and CFO, Director, 10%+ Owner
Signature
/s/ Snehal Patel
Issuer symbol
GLSI
Transactions as of
22 Jun 2022
Net transactions value
$0
Form type
4
Filing time
24 Jun 2022, 08:16:46 UTC
Previous filing
17 Jun 2022
Next filing
27 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLSI Stock Options Award $0 +1,048,723 $0.000000 1,048,723 22 Jun 2022 Common Stock 1,048,723 $7.63 Direct F1
transaction GLSI Stock Options Award $0 +25,008 +2.4% $0.000000 1,073,731 22 Jun 2022 Common Stock 25,008 $7.63 By Wife F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest over time and pursuant to milestones. 21,848 of the options vest each month for 48 months contingent on the Company meeting certain performance milestones. The Reporting Person is eligible to exercise (i) 20% of the vested options after $10 million is raised by the Company (ii) 20% after the first site is activated for the Phase 3 clinical trial, (iii) 40% after completion of interim analysis of the Phase 3 clinical trial and (iv) 20% upon filing of Biologic License Application with the US Food and Drug Administration.
F2 521 options vest each month for 48 months.